Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05550207 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
A Phase 3 study of Migraine, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05550207 is a Phase 3 study of Migraine that has completed, run by Axsome Therapeutics. The registered enrollment target is 100 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05550207, a Phase 3 study of Migraine, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
Conditions Studied
Interventions
- DRUG AXS-07 (meloxicam-rizatriptan)
Study Locations (20)
Florida
- Clinical Research Site - DeLand
- Clinical Research Site - Hallandale
- Clinical Research Site - Hollywood
- Clinical Research Site - Miami
- Clinical Research Site - Ormond Beach
- Clinical Research Site - Oviedo
- Clinical Research Site - Pensacola
- Clinical Research Site - Winter Park
California
- Clinical Research Site - Colton
- Clinical Research Site - Fullerton
- Clinical Research Site - La Jolla
- Clinical Research Site - Los Angeles
- Clinical Research Site - Sherman Oaks
Massachusetts
- Clinical Research Site - Boston
- Clinical Research Site - North Dartmouth
Connecticut
- Clinical Research Site - Stamford
Georgia
- Clinical Research Site - Stockbridge
Indiana
- Clinical Research Site - Avon
Nevada
- Clinical Research Site - Las Vegas
New Mexico
- Clinical Research Site - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2024-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05550207
The ClinicalTrials.gov registry entry for NCT05550207 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower). The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which AXS-07 (meloxicam-rizatriptan) is the first listed.
NCT05550207 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05550207 about?
NCT05550207 is a clinical study titled "Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)". This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
What is the current status of trial NCT05550207?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2022-08-31. Estimated completion is 2024-11-27.
What conditions does trial NCT05550207 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05550207?
The interventions under investigation include: AXS-07 (meloxicam-rizatriptan) (DRUG).
Who is sponsoring clinical trial NCT05550207?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05550207 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.